צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: sonnetbio.com (SONN)

The use of AI protein modeling has strengthened the professional image of Sonnet BioTherapeutics (SONN) within the targeted cytokine niche. The trailing 12-month sales growth relative to the previous year illustrates this process, where the 1697.80 level represents the current value. However, the absence of commercial products and a reliance on external capital render the company's financial position unstable.
Sonnet BioTherapeutics (SONN) - פילוחי מדדים ודוחות פיננסיים

The virtual model of Sonnet BioTherapeutics (SONN) utilizing R&D outsourcing makes the company dependent on the efficiency of external contractors. This indicator calculates the percentage change in revenue over a rolling year, neutralizing seasonal fluctuations. The metric allows for an assessment of the business's real operational expansion from a fundamental perspective. Investors should keep in mind that even a positive trend does not guarantee capital protection during a cycle shift. By analyzing the TTM revenue growth rate compared to the previous year, one can judge the scalability of the current strategy.